Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05371717
Other study ID # 2022-GASTRO
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 1, 2022
Est. completion date May 20, 2024

Study information

Verified date February 2024
Source University of Pavia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to evaluate dental erosion in patients with gastroesophageal reflux disease (GERD). Patients consenting to participate to the study will undergo periodontal evaluation at the baseline. Then, professional dental hygiene will be performed. Patients will be randomly assigned to: - Trial group: home oral hygiene with Biorepair Total Protection + Biorepair Shock Treatment twice a day - Control group: home oral hygiene with Biorepair Total Protection Patients will be evaluated after 1, 3 and 6 months from baseline.


Description:

The aim of the present study is to evaluate dental erosion in patients with gastroesophageal reflux disease (GERD). Patients consenting to participate to the study will undergo periodontal evaluation at the baseline. Then, professional dental hygiene will be performed. Patients will be randomly assigned to: - Trial group: home oral hygiene with Biorepair Total Protection + Biorepair Shock Treatment twice a day - Control group: home oral hygiene with Biorepair Total Protection Patients will be evaluated after 1, 3 and 6 months from baselin


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date May 20, 2024
Est. primary completion date May 17, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - patients with dental erosion - no proton pumps before pH examination Exclusion Criteria: - no dental erosion - neurological and psychiatric diseases; - pregnant and/or breastfeeding women; - patients with poor compliance.

Study Design


Intervention

Other:
Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment
Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
Biorepair Total Protection
Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.

Locations

Country Name City State
Italy Unit of Dental Hygiene - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia Pavia Lombardy

Sponsors (1)

Lead Sponsor Collaborator
University of Pavia

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of BEWE (Basic Erosive Wear Examination) Scoring criteria (Barlet et al., 2008):
0: no erosive tooth wear;
1: initial loss of surface texture;
2: distinct defect, hard tissue loss < 50% of the surface area;
3: hard tissue loss = 50% of the surface area.
IntactTooth smartphone application will be used to calculate this index.
Study begin, 1, 3 and 6 months after the baseline
Primary Change in Schiff Air Index - Dental sensitivity test Scoring criteria:
0: the subject did not respond to air blasting;
the subject responded to air blasting;
the subject responded to air blasting and requested discontinuation;
the subject responded to air blasting, requested discontinuation and considered the stimulus to be painful.
Study begin, 1, 3 and 6 months after the baseline
Primary Change in Plaque Index (PI% - O' Leary Index) Evaluation of the presence of plaque on the 4 surfaces of teeth on the total amount of dental surfaces.
Formula = n ° sites with plaque / total n ° of dental surfaces x100
Study begin, 1, 3 and 6 months after the baseline
Primary Change in Bleeding Score (BS - Mombelli et al.) Scoring criteria:
0: no bleeding
isolated visible spots
blood forms a confluent red line on the mucosal margin
profuse and copious bleeding
Study begin, 1, 3 and 6 months after the baseline
Primary Laryngopharyngeal pH monitoring pH monitoring Data was collected wirelessly for 24 hours and then analysed. Length, severity and number of reflux episodes were calculated. The RYAN score was used to evaluate for laryngopharyngeal acid reflux and was calculated for both the upright and supine positions. A RYAN score >9.4 in the upright position or >6.8 in the supine position was considered positive. Patients with a positive RYAN score in either the upright or supine positions were considered positive for laryngopharyngeal acid reflux. Study begin, 1, 3 and 6 months after the baseline
Primary Erosion risk level For each sextant, the highest BEWE value will be chosen. A mean of all the sextant values will be performed to calculate erosion risk level.
IntactTooth smartphone application will be used to calculate this index.
Study begin, 1, 3 and 6 months after the baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06025773 - A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121 Phase 1
Recruiting NCT06280664 - Efficacy Of Hiatal Closure For GERD
Recruiting NCT05359965 - Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF N/A
Completed NCT04202692 - Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment N/A
Active, not recruiting NCT03646045 - Transpyloric Feeding for Prevention of Micro-aspiration
Recruiting NCT06430047 - Efficacy and Safety of EsoDuo® Phase 4
Completed NCT04268719 - Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
Active, not recruiting NCT04614974 - Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia Phase 1/Phase 2
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Recruiting NCT03868267 - Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
Terminated NCT04028466 - Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features Phase 4
Recruiting NCT05066594 - Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)
Completed NCT03476265 - Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility N/A
Completed NCT03143608 - GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery N/A
Completed NCT04436159 - Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia. N/A
Completed NCT03258528 - Effect of Right Lateral Position on Ventilated Preterm Neonates N/A
Active, not recruiting NCT04500288 - The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study N/A
Completed NCT04262648 - Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns N/A
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Active, not recruiting NCT03835663 - The Bacterial Composition of the Stomach in Reflux Disease